Bio-Rad Laboratories, Inc. (BIO) Presents At Wells Fargo 20th Annual Healthcare Conference 2025 (Transcript)

Bio-Rad Laboratories reported a strong Q2 revenue beat, driven by stabilized end markets, over 50% growth in process chromatography, and consistent consumable pull-through, which also improved operating margins as tariff impacts stabilized. Strategic initiatives include the Stilla acquisition, targeting accretion within 18-24 months, and an expanded ddPCR portfolio aiming for mid-single-digit growth, though instrument sales remain soft in biopharma and academic/government sectors amid budget uncertainties and China's reimbursement pressures. Management is focused on operational efficiencies, including supply chain and working capital, targeting 3%+ top-line growth for margin expansion, and views its undervalued Sartorius stake as a key monetizable asset providing optionality, with a spring 2026 Investor Day planned to outline new multi-year targets.

Analysis

Bio-Rad Laboratories reported a significant Q2 revenue beat, signaling a stabilization in end markets. This was primarily driven by exceptional growth in the process chromatography business, which exceeded 50% year-over-year due to a specific customer pull-in, prompting a guidance increase for the segment to low-double-digit growth for the full year. Strong, consistent consumable pull-through further supported the top line and contributed to improved operating margins. Margin expansion was also aided by a stabilization of the tariff situation, with the expected headwind for the year reduced from 130 basis points to approximately 30-40 basis points. Despite these positive developments, significant headwinds persist. Instrument sales remain challenged across smaller biopharma and academic & government (A&G) sectors, with management expecting the U.S. A&G market to remain sequentially similar to Q2, without a significant year-end budget flush, pending NIH budget finalization. Geographically, Europe faces pressure while China's market is soft, compounded by a reimbursement rate cut on the A1c test creating a $15-20 million annual headwind for the diagnostics business.

Strategically, the company is focused on reigniting growth through its expanded Droplet Digital PCR (ddPCR) portfolio, bolstered by the recent Stilla acquisition and the launch of the Continuum platform. Management is guiding for ddPCR growth to accelerate from low-single to mid-single digits in the near term, with a long-term ambition for high-single to double-digit growth. The Stilla acquisition is expected to be accretive within 18-24 months. Operationally, there is a strong focus on enhancing efficiency, particularly in working capital, where management acknowledged inventory turns of 1.5x are "abysmal" and present a clear opportunity for improving free cash flow. The company stated it requires top-line growth of at least 3% to achieve margin expansion and plans to provide an updated three-year financial model at an investor day in the spring.

Key Decisions for Investors

• Investors should monitor execution on the guided Q4 revenue ramp, which relies on specific drivers like Quality Systems lot releases and the initial uptake of the expanded ddPCR portfolio, as this will be a key test of management's ability to deliver on its growth initiatives.
• Given the bifurcation between stable consumable sales and weak instrument demand, a key catalyst for the stock will be a recovery in capital spending from biopharma and academic clients; watch for commentary around the finalized NIH budget and instrument order book trends, while noting management's caution that any rebound will be gradual.
• Consider the company's significant operating leverage, as management has identified a 3% growth threshold for margin expansion and highlighted major inefficiencies in working capital that could unlock substantial free cash flow; the potential monetization of the highly-valued Sartorius stake also remains a significant, albeit undefined, source of future optionality for M&A or shareholder returns.